PPV of CagA and CagA-signaling molecules for HP dependence of stage IE/IIE1 gastric DLBCL
| Expression of CagA and CagA-signaling molecules in tumor tissue . | No. of gastric DLBCL patients who receive HPE as frontline treatment . | |
|---|---|---|
| HP dependent, n = 28 . | HP independent, n = 25 . | |
| CagA positive | 22 | 7 |
| CagA negative | 6 | 18 |
| PPV for CagA* = 22 of 29 (75.9%) | ||
| Specificity for CagA† = 18 of 25 (75.0%) | ||
| p-SHP-2 positive | 21 | 7 |
| PPV for p-SHP-2* = 21 of 28 (75.0%) | ||
| p-ERK positive | 22 | 10 |
| PPV for p-ERK* = 22 of 32 (68.8%) | ||
| CagA, p-SHP-2, and p-ERK are all positive | ||
| Yes | 18 | 4 |
| No | 10 | 21 |
| PPV for combined CagA, p-SHP-2, and p-ERK‡ = 18 of 22 (81.8%) | ||
| Specificity for combined CagA, p-SHP-2, and p-ERK§ = 21 of 25 (84.0%) | ||
| Expression of CagA and CagA-signaling molecules in tumor tissue . | No. of gastric DLBCL patients who receive HPE as frontline treatment . | |
|---|---|---|
| HP dependent, n = 28 . | HP independent, n = 25 . | |
| CagA positive | 22 | 7 |
| CagA negative | 6 | 18 |
| PPV for CagA* = 22 of 29 (75.9%) | ||
| Specificity for CagA† = 18 of 25 (75.0%) | ||
| p-SHP-2 positive | 21 | 7 |
| PPV for p-SHP-2* = 21 of 28 (75.0%) | ||
| p-ERK positive | 22 | 10 |
| PPV for p-ERK* = 22 of 32 (68.8%) | ||
| CagA, p-SHP-2, and p-ERK are all positive | ||
| Yes | 18 | 4 |
| No | 10 | 21 |
| PPV for combined CagA, p-SHP-2, and p-ERK‡ = 18 of 22 (81.8%) | ||
| Specificity for combined CagA, p-SHP-2, and p-ERK§ = 21 of 25 (84.0%) | ||
PPV: Number of HP-dependent cases who had CagA expression or CagA-signaling molecules expression divided by the number of the total positive cases for respective CagA expression or CagA-signaling molecule expression.
Specificity: Number of HP-independent cases who had no CagA expression/total HP-independent cases.
PPV: Number of HP-dependent cases who had all CagA, p-SHP-2, and p-ERK expression/total cases expressing all CagA, p-SHP-2, and p-ERK.
Specificity: Number of HP-independent cases who did not simultaneously express CagA, p-SHP-2, and p-ERK in tumors/total HP-independent cases.